Breast Atypical Hyperplasia — Trials

Breast Atypical Hyperplasia — Trials · CancerIndex

Clinical trials

Registered studies

21 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

clinicaltrialsPublishedShowing 1–6 of 6 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04570956	Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia, Lobular Carcinoma In Situ, or Increased Breast Cancer Risk	terminated	Phase 2	65	Mayo ClinicOTHER	1	Sep 24, 2026	clinicaltrials
NCT06195306	Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction	recruiting	Phase 2	66	National Cancer Institute (NCI)NIH	1	Aug 4, 2026	clinicaltrials
NCT06184750	Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial	recruiting	Phase 2	200	National Cancer Institute (NCI)NIH	1	Jul 27, 2026	clinicaltrials
NCT05941520	Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer

Data updated 4 days agoSource updated Sep 24, 2026source: clinicaltrials